Loading
NASDAQHealthcareBiotechnology
Latest quote
$24.62
+$0.72 · +3.01%
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
Previous close
$24.62
+$0.72 · +3.01%
After-hours
$24.62
$0.00 · 0.00%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
Day range
Current $24.62
52-week range
Current $24.62
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
46
Mixed
Risk
53
Elevated Risk
Momentum
58
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
Day range
Current $24.62
52-week range
Current $24.62
| Metric (USD) | FY2025 |
|---|---|
| Cost of goods sold | 612K USD |
| Gross profit | −612K USD |
| Research and development | 28.64M USD |
| Selling, general, and administrative | 12.2M USD |
| Operating expenses | 40.84M USD |
| Interest income | 3.11M USD |
| Depreciation and amortization | 612K USD |
| Operating income | −41.45M USD |
| Net income | −39.87M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$38.00
54.35% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI8.28M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM5.94M0.01%77.7B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF2.96M0.00%95.4B USD0.05%$233.13-0.15%
Vanguard Russell 2000 ETFVTWO1.66M0.01%18B USD0.06%$112.1-0.10%
iShares Russell 2000 Growth ETFIWO1.43M0.01%14.04B USD0.24%$353.47-0.53%
ALPS Medical Breakthroughs ETFSBIO1.01M0.54%188.26M USD0.50%$53.945-0.34%
Avantis Emerging Markets Equity ETFAVEM1.01M—28.72B USD0.33%$93.24-1.80%
Schwab U.S. Small-Cap ETFSCHA844.38K0.00%21.7B USD0.03%$32.66+0.15%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOALPS Medical Breakthroughs ETFSBIOAvantis Emerging Markets Equity ETFAVEMSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
